Editas Medicine Inc

NASDAQ:EDIT  
2.57
+0.01 (+0.39%)
4:59:56 PM EDT: $2.60 +0.03 (+1.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)215.98M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.31 Million
Adjusted EPS-$0.39
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Editas Medicine Inc Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.401.9000
Number of Employees: 246

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.